Aud

The Civic Center Committee Partners with Norwich University, Senator Bernie Sanders to Update the Historic Barre Auditorium

Retrieved on: 
Thursday, April 20, 2023
Civic, Armstrong, Barre Auditorium, University, Emergency shelter, Table, Central Vermont Medical Center, Teaching, Electricity, COVID, Architecture, Wind, Feasibility study, Aud, Student, City, Higby, Art, Engineering, Construction management, International Red Cross and Red Crescent Movement, School, Ageing, Female, Norwich University, Interior design, Whaling, Civil engineering, Tourism, Nursing, Barre City Hall and Opera House

The historic Barre Auditorium has long been a community hub in the city of Barre.

Key Points: 
  • The historic Barre Auditorium has long been a community hub in the city of Barre.
  • Lately, though, it has been somewhat of a second classroom for Norwich architecture, engineering, and construction management students.
  • The building itself has aged, and Sue Higby, vice chair of the Civic Center Committee, which is responsible for the auditorium, decided that Norwich might be of help to improve the building.
  • “I reached out to Dr. Michael Kelley and started a relationship early on in the fall of 2021,” she said.

Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder

Retrieved on: 
Thursday, July 29, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical trials, Psychoactive drugs, Branches of biology, Neurochemistry, Drinking culture, Substance dependence, Aud, RNA interference, Alcoholism, Investigational New Drug, Alcohol, Alcohol Use Disorder (AUD), DCR-AUD, RNAi and Dicerna’s GalXC™ RNAi Platform Technologies, Dicerna Pharmaceuticals, Inc., ALCOHOL USE DISORDER (AUD), DCR-AUD, RNAI AND DICERNA’S GALXC™ RNAI PLATFORM TECHNOLOGIES, DICERNA PHARMACEUTICALS, INC.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for DCR-AUD, the Companys investigational RNAi candidate for the treatment of alcohol use disorder (AUD).

Key Points: 
  • Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for DCR-AUD, the Companys investigational RNAi candidate for the treatment of alcohol use disorder (AUD).
  • RNAis long duration of effect and target specificity can achieve liver-specific reduction of ALDH2, which could be an effective strategy to reduce alcohol consumption.
  • The trial will also assess the interaction between DCR-AUD treatment and alcohol consumption using standardized Ethanol Interaction Assessments.
  • Alcohol use disorder, or AUD, is a chronic disorder characterized by the inability to stop or control alcohol use despite social, occupational or health consequences.

SS&C Advances Offer on Acquisition of Mainstream Group

Retrieved on: 
Friday, May 14, 2021
SS&C Technologies, Windsor, Connecticut, Aud

b'WINDSOR, Conn., May 14, 2021 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that it has amended the Scheme Implementation Deed with Mainstream Group Holdings Limited (ASX: MAI, "Mainstream") to provide for an acquisition by SS&C of 100% of the shares and outstanding equity rights in Mainstream for A$2.61 per security pursuant to a scheme of arrangement.

Key Points: 
  • b'WINDSOR, Conn., May 14, 2021 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that it has amended the Scheme Implementation Deed with Mainstream Group Holdings Limited (ASX: MAI, "Mainstream") to provide for an acquisition by SS&C of 100% of the shares and outstanding equity rights in Mainstream for A$2.61 per security pursuant to a scheme of arrangement.
  • As at March 2021, Mainstream provides administration services to 1,364 funds and more than 176,000 investors with funds under administration of AUD $272 billion.
  • Mainstream employs 330 people, with operations in Australia, Singapore, Hong Kong, the United States, the Isle of Man, Malta, Ireland and the Cayman Islands.
  • For more information, please visit: https://www.mainstreamgroup.com .\nSS&C is a global provider of services and software for the financial services and healthcare industries.

SS&C Updates Increased Offer on Acquisition of Mainstream Group

Retrieved on: 
Thursday, April 29, 2021
Microsoft, Countries, Software, SS&C Technologies, Windsor, Connecticut, LinkedIn, Twitter, MALTA, Aud

As at March 2021, Mainstream provides administration services to 1,364 funds and more than 176,000 investors with funds under administration of AUD $272 billion.

Key Points: 
  • As at March 2021, Mainstream provides administration services to 1,364 funds and more than 176,000 investors with funds under administration of AUD $272 billion.
  • Mainstream employs 330 people, with operations in Australia, Singapore, Hong Kong, the United States, the Isle of Man, Malta, Ireland and the Cayman Islands.
  • For more information, please visit: https://www.mainstreamgroup.com .\nSS&C is a global provider of services and software for the financial services and healthcare industries.
  • Follow SS&C on Twitter, LinkedIn and Facebook.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/ssc-updates-increased-offer-on-a...\n'

SS&C Updates Offer on Acquisition of Mainstream Group

Retrieved on: 
Tuesday, April 27, 2021
SS&C Technologies, Windsor, Connecticut, Aud

b'WINDSOR, Conn., April 27, 2021 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that it has amended the Scheme Implementation Deed with Mainstream Group Holdings Limited (ASX: MAI, "Mainstream") to provide for an acquisition by SS&C of 100% of the shares and outstanding equity rights in Mainstream for A$2.25 per security pursuant to a scheme of arrangement.

Key Points: 
  • b'WINDSOR, Conn., April 27, 2021 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that it has amended the Scheme Implementation Deed with Mainstream Group Holdings Limited (ASX: MAI, "Mainstream") to provide for an acquisition by SS&C of 100% of the shares and outstanding equity rights in Mainstream for A$2.25 per security pursuant to a scheme of arrangement.
  • As at December 2020, Mainstream provides administration services to 1,202 funds and more than 157,000 investors with funds under administration of AUD $224 billion.
  • Mainstream employs 305 people, with operations in Australia, Singapore, Hong Kong, the United States, the Isle of Man, Malta, Ireland and the Cayman Islands.
  • For more information, please visit: https://www.mainstreamgroup.com .\nSS&C is a global provider of services and software for the financial services and healthcare industries.

SS&C Offers to Acquire Mainstream Group

Retrieved on: 
Monday, April 12, 2021
Programming languages, Computer programming, SS&C Technologies, Windsor, Connecticut, Aud, Cond, Scheme

b'WINDSOR, Conn., April 12, 2021 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that it has entered into a conditional Scheme Implementation Deed with Mainstream Group Holdings Limited (ASX: MAI, "Mainstream").

Key Points: 
  • b'WINDSOR, Conn., April 12, 2021 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that it has entered into a conditional Scheme Implementation Deed with Mainstream Group Holdings Limited (ASX: MAI, "Mainstream").
  • The Scheme Implementation Deed entered into by SS&C is conditional on the ultimate outcome of that matching right process.
  • As at December 2020, Mainstream provides administration services to 1,202 funds and more than 157,000 investors with funds under administration of AUD $224 billion.
  • Mainstream employs 305 people, with operations in Australia, Singapore, Hong Kong, the United States, the Isle of Man, Malta, Ireland and the Cayman Islands.

Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 25, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Science, Clinical trials, RNA, Aud, RNA interference, Biology, Biotechnology, Life sciences

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update.

Key Points: 
  • Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update.
  • Clinical Development Candidate DCR-AUD for Alcohol Use Disorder (AUD) To Enter Clinical Development in the Third Quarter of 2021.
  • Today, Dicerna announced its third wholly owned clinical development program, an investigational therapy based on Dicernas GalXC technology for the treatment of AUD.
  • ET today to review Dicerna's full year 2020 financial results and provide a general business update.

Global Alcohol Use Disorder Market to 2030 - Insight, Epidemiology and Market Forecast - ResearchAndMarkets.com

Retrieved on: 
Friday, October 30, 2020
Pharmaceutical, Health, Mental health, Psychiatric diagnosis, Substance dependence, Drinking culture, Alcoholism, Aud

The "Alcohol Use Disorder (AUD) - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alcohol Use Disorder (AUD) - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The market size of Alcohol Use Disorder is expected to increase at a significant CAGR during the study period (2017-2030).
  • Among all the seven major markets, the United States accounted for the largest Alcohol Use Disorder market size.
  • The report also covers current Alcohol Use Disorder treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities.

Biom'up Australian Market Growth Gathers Pace

Retrieved on: 
Thursday, October 8, 2020
Hemostat, Aud, Marketplace, Addressable

The partnership has positioned Biom'up to make substantial inroads into the growing Australian market through LifeHealthcare's wide commercial footprint in the market.

Key Points: 
  • The partnership has positioned Biom'up to make substantial inroads into the growing Australian market through LifeHealthcare's wide commercial footprint in the market.
  • "The introduction of HEMOBLASTBellows to the Australian market has been a formidable initial success.
  • The results and feedback from the physician usage have confirmed our confidence in our product's value-add and bodes well for Biom'up's prospects in the Australian market," says Patrice Ferrand, Group CEO of Biom'up.
  • "With the total Australian hemostat market valued at $59M AUD, of which $35M addressable is combination hemostats, there is no doubt that there is a solid role for HEMOBLAST Bellows to play in this market.

MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN‑166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual Convention

Retrieved on: 
Thursday, August 6, 2020
RTT, Psychiatric diagnosis, Aud, Alcoholism

A total of 52 alcohol use disorder (AUD) patients were enrolled in this trial.

Key Points: 
  • A total of 52 alcohol use disorder (AUD) patients were enrolled in this trial.
  • This is the first study to show the positive effect of MN-166 to attenuate activation in the brain in a neuroimaging study.
  • We are thrilled that MN-166 has demonstrated great potential to reduce the increasing problem of alcohol use disorder.
  • Professor Lara Ray commented, We are very excited to report the positive data from our Phase 2 clinical trial in AUD.